ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
38 announcements with these filters
RPG Life Sciences delivered strong Q4 FY26 performance with 23.6% revenue growth and 58.1% PAT growth (excl. exceptions), driven by Domestic Formulations and margin expansion.
RPG Life Sciences Limited appointed Dr. Pratit Samdani as a Non-Executive Independent Director for a five-month term effective April 29, 2026. Dr. Samdani is a highly respected physician with over two decades of experience in Internal Medicine and Critical Care.
RPG Life Sciences Limited has recommended a final dividend of 300% per equity share for the period ended April 2026. The record date and general meeting date for shareholder approval are yet to be fixed. This follows a board meeting concluded on April 29, 2026.
RPG Life Sciences reported a 23.6% Y-o-Y revenue increase to ₹176.9 Crore for Q4 FY26, with an EBITDA margin of 25.6%. Full-year FY26 revenue grew 8.3% to ₹707.5 Crore. The Board recommended a 300% dividend (₹24 per share). Growth was driven by robust performance in Domestic Formulations and a strong recovery in the API division.
RPG Life Sciences Ltd reported revenue from operations of ₹176.9 Cr (+23.6% YoY) and net profit of ₹29.9 Cr (-74.5% YoY) for Q4 FY26.
RPG Life Sciences Limited reported a standalone total income of ₹733.06 Crore for the year ended March 31, 2026. The Board recommended a dividend of ₹24 (300%) per equity share and appointed Dr. Pratit Samdani as an Additional Non-Executive Independent Director for five years.
Clarus Capital I acquired 1,45,113 shares (0.88% stake) of RPG Life Sciences Limited via the open market on April 17, 2026. This acquisition increased its total holding from 4.53% to 5.41%, crossing the 5% disclosure threshold under SEBI SAST Regulations.
RPG Life Sciences Ltd reported net profit of ₹22.1 Cr (-36.7% YoY) for Q3 FY26.